An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients
Public ClinicalTrials.gov record NCT02555709. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Psoriatic Patients and Clinical Proof-of-Concept in Psoriatic Patients
Study identification
- NCT ID
- NCT02555709
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
- Industry
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Interventions
- Placebo 1 Drug
- Placebo 2 Drug
- VTP-43742 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2015
- Primary completion
- Feb 29, 2016
- Completion
- Feb 29, 2016
- Last update posted
- Oct 29, 2018
2015 – 2016
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Patient Site 5 | Rogers | Arkansas | 72758 | — |
| Patient Site 1 | Miami | Florida | 33144 | — |
| Patient Site 8 | Tampa | Florida | 33609 | — |
| Patient 12 | Tampa | Florida | 33624 | — |
| Patient Site 13 | Carmel | Indiana | 46032 | — |
| Patient Site 4 | Plainfield | Indiana | 46168 | — |
| Healthy Volunteer Site 1 | Fair Lawn | New Jersey | 07410 | — |
| Patient Site 2 | New York | New York | 10012 | — |
| Patient Site 9 | High Point | North Carolina | 27265 | — |
| Patient Site 6 | College Station | Texas | 77845 | — |
| Patient Site 3 | Dallas | Texas | 75231 | — |
| Patient Site 10 | Houston | Texas | 77004 | — |
| Patient Site 11 | Houston | Texas | 77065 | — |
| Patient Site 7 | Webster | Texas | 77598 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02555709, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2018 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02555709 live on ClinicalTrials.gov.